Market revenue in 2023 | USD 12,710.8 million |
Market revenue in 2030 | USD 19,479.7 million |
Growth rate | 6.3% (CAGR from 2023 to 2030) |
Largest segment | Tablets |
Fastest growing segment | Capsules |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Tablets, Capsules, Powders, Granules |
Key market players worldwide | Catalent Inc, Lonza Group Ltd, Boehringer Ingelheim, Jubilant Pharmova, Novacyt SA, Thermo Fisher Scientific Inc, Recipharm, CordenPharma, Siegfried Holding AG, Piramal Pharma Solutions, AbbVie Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to oral solid dosage contract manufacturing market will help companies and investors design strategic landscapes.
Tablets was the largest segment with a revenue share of 33.44% in 2023. Horizon Databook has segmented the Asia Pacific oral solid dosage contract manufacturing market based on tablets, capsules, powders, granules covering the revenue growth of each sub-segment from 2018 to 2030.
Asia Pacific held the largest market share of 34.8% in 2023 and is expected to maintain this dominance over the forecast period. This growth can be attributed to various factors such as improved social insurance schemes and constantly improving economic conditions in the region, which allow patients to pay out-of-pocket pharmaceutical costs.
In addition, in the past decade, manufacturing of pharmaceutical products has been outsourced to Asian countries, including India and China. Furthermore, the availability of a large number of potential study subjects has driven several pharmaceutical companies, such as Eli-Lilly and GlaxoSmithKline, to conduct clinical studies in Asian countries such as India.
The presence of government-sponsored financial incentive programs in China and India to harmonize the FDA approval process is anticipated to accelerate the growth of the oral solid dosage contract manufacturing market in this region.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific oral solid dosage contract manufacturing market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific oral solid dosage contract manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account